Improved Quality of the Treatment and Increased Compliance in Asthmatics Through the Dialog Tool Soren - Between Patient and Caregiver

This study is ongoing, but not recruiting participants.

Sponsored by:	AstraZeneca
Information provided by:	AstraZeneca
ClinicalTrials.gov Identifier:	NCT00272727

Purpose

The purpose of the study is to assess if a dialog tool can improve compliance and asthma control in patients with asthma.

Condition	Intervention
Asthma	Behavioral: Dialog tool for caregivers

MedlinePlus related topics: Asthma Caregivers

Study Type:	Interventional
Study Design:	Educational/Counseling/Training, Randomized, Open Label, Placebo Control, Crossover Assignment, Efficacy Study
Official Title:	Improved Quality of the Treatment and Increased Compliance in Asthmatics Through the Dialog Tool Soren - Between Patient and Caregiver

Further study details as provided by AstraZeneca:

Primary Outcome Measures:

Secondary Outcome Measures:

Estimated Enrollment:	100
Study Start Date:	January 2006

Eligibility

Criteria

Inclusion Criteria:

Exclusion Criteria:

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00272727

Locations

Sponsors and Collaborators

AstraZeneca

Investigators

Study Director:

AstraZeneca Denmark Medical Director, MD

AstraZeneca

More Information

Study ID Numbers:	AZ-SOREN, SOREN
Study First Received:	January 4, 2006
Last Updated:	November 30, 2006
ClinicalTrials.gov Identifier:	NCT00272727
Health Authority:	Denmark: Danish Medicines Agency

Keywords provided by AstraZeneca:

Asthma
dialog tool
compliance

Study placed in the following topic categories:

Hypersensitivity
Lung Diseases, Obstructive
Respiratory Tract Diseases
Lung Diseases

Hypersensitivity, Immediate
Asthma
Respiratory Hypersensitivity

Additional relevant MeSH terms:

Immune System Diseases
Bronchial Diseases

ClinicalTrials.gov processed this record on January 16, 2009